Literature DB >> 35705500

Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest-Old.

Thomas J Montine1, Maria M Corrada2,3, Claudia Kawas2,4, Syed Bukhari1, Lon White5, Lu Tian6, Brenna Cholerton7.   

Abstract

BACKGROUND AND OBJECTIVES: Age is the largest risk factor for dementia. However, dementia is not universal, even among the oldest-old age groups. Following contemporary neuropathologic guidelines, our objectives were to describe the key neuropathologic lesions and their associations with antemortem cognition in oldest-old individuals.
METHODS: Participants were those enrolled in The 90+ Study, a longitudinal, population-based study of aging/dementia in the oldest-old, who agreed to postmortem brain examination. All autopsied brains as of December 2020 were evaluated for prevalence of Alzheimer's disease neuropathologic change (ADNC) and non-ADNC neuropathologic comorbidities. Associations between neuropathologic lesions or total neuropathologic burden score (sum of the individual scores) and cognition were assessed using multinomial logistic regression and multiple linear regression. Separate regression analyses evaluated relationships between limbic-predominant age-related TDP-43 encephalopathy (LATE-NC) and hippocampal sclerosis (HS) or ADNC/primary age-related tauopathy (PART). Resistance, or failure to develop ADNC/PART, and resilience, inferred from higher than expected cognitive functioning, were evaluated in the presence or absence of non-ADNC neuropathologic features.
RESULTS: The most common neuropathologic features in the sample (n=367) were ADNC/PART-related. Increased dementia odds were associated with elevated total neuropathologic burden (OR=1.5 [95% CI 1.3-1.7] p<0.0001), beta amyloid (OR=1.6 [95% CI 1.2-2.0] p<0.0001), neurofibrillary tangles (OR=2.6 [95% CI 1.7-4.1] p<0.0001), and LATE-NC (OR=2.3 [95% CI 1.7-3.1] p<0.0001), correcting for multiple comparisons. LATE-NC was associated with dementia with (OR=6.1 [95% CI 2.0-18.7] p=0.002) and without (OR=5.0 [95% CI 2.6-9.7] p<0.0001) co-occurring HS, and increased the odds of dementia among participants with ADNC (OR=5.0 [95% CI 2.7-9.2] p<0.0001). Resistance to moderate/severe ADNC/PART was rare (3%), but resilience to ADNC/PART was not (55%). Resilience was rarer in the presence of non-ADNC comorbid lesions, particularly LATE-NC. Among those with moderate/severe ADNC/PART, dementia odds increased with each non-ADNC comorbid lesion (e.g., 1 lesion: OR=2.4 [95% CI 1.3-4.5] p<0.005; 2 lesions: OR=5.9 [95% CI 2.8-12.3] p<0.0001).
CONCLUSION: These results highlight the importance of non-ADNC neuropathologic comorbidity, predominantly LATE-NC, to cognition in the oldest-old. Given the cumulative effects of non-ADNC comorbid neuropathologic abnormalities, reducing their prevalence, especially LATE-NC, will be vital to the ultimate goal of reducing dementia burden in the oldest-old individuals.
© 2022 American Academy of Neurology.

Entities:  

Year:  2022        PMID: 35705500      PMCID: PMC9519247          DOI: 10.1212/WNL.0000000000200832

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   11.800


  46 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Norms for letter and category fluency: demographic corrections for age, education, and ethnicity.

Authors:  J A Gladsjo; C C Schuman; J D Evans; G M Peavy; S W Miller; R K Heaton
Journal:  Assessment       Date:  1999-06

3.  Impact of interventions to reduce Alzheimer's disease pathology on the prevalence of dementia in the oldest-old.

Authors:  Ron Brookmeyer; Claudia H Kawas; Nada Abdallah; Annlia Paganini-Hill; Ronald C Kim; María M Corrada
Journal:  Alzheimers Dement       Date:  2016-02-17       Impact factor: 21.566

4.  Prevalence and severity of cognitive impairment with and without dementia in an elderly population.

Authors:  J E Graham; K Rockwood; B L Beattie; R Eastwood; S Gauthier; H Tuokko; I McDowell
Journal:  Lancet       Date:  1997-06-21       Impact factor: 79.321

5.  Phases of A beta-deposition in the human brain and its relevance for the development of AD.

Authors:  Dietmar R Thal; Udo Rüb; Mario Orantes; Heiko Braak
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

6.  Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies.

Authors:  Caitlin S Latimer; C Dirk Keene; Margaret E Flanagan; Laura S Hemmy; Kelvin O Lim; Lon R White; Kathleen S Montine; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2017-06-01       Impact factor: 3.148

Review 7.  Concepts for brain aging: resistance, resilience, reserve, and compensation.

Authors:  Thomas J Montine; Brenna A Cholerton; Maria M Corrada; Steven D Edland; Margaret E Flanagan; Laura S Hemmy; Claudia H Kawas; Lon R White
Journal:  Alzheimers Res Ther       Date:  2019-03-11       Impact factor: 6.982

Review 8.  Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review.

Authors:  Hannah A D Keage; Roxanna O Carare; Robert P Friedland; Paul G Ince; Seth Love; James A Nicoll; Stephen B Wharton; Roy O Weller; Carol Brayne
Journal:  BMC Neurol       Date:  2009-01-13       Impact factor: 2.474

9.  Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging.

Authors:  Alifiya Kapasi; Lei Yu; Patricia A Boyle; Lisa L Barnes; David A Bennett; Julie A Schneider
Journal:  Neurology       Date:  2020-08-04       Impact factor: 9.910

10.  Application of an Imaging-Based Sum Score for Cerebral Amyloid Angiopathy to the General Population: Risk of Major Neurological Diseases and Mortality.

Authors:  Pinar Yilmaz; Mohammad Arfan Ikram; Mohammad Kamran Ikram; Wiro J Niessen; Anand Viswanathan; Andreas Charidimou; Meike W Vernooij
Journal:  Front Neurol       Date:  2019-12-06       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.